AstraZeneca Considers US Stock Listing as CEO Highlights Expansion and Investment Plans

AstraZeneca CEO Pascal Soriot discusses the company's focus on the US market, including potential stock listing changes and a $50 billion investment plan aimed at achieving signifi...